환자 유래 이종 이식/PDX 모델 시장 - 세계 예측(2026-2032년)

The Patient-Derived Xenograft/PDX Model Market is projected to grow by USD 1,591.33 million at a CAGR of 15.02% by 2032.

Patient-Derived Xenograft Models Move Toward Precision Oncology Relevance

Patient-derived xenograft (PDX) models are preclinical cancer research platforms created by implanting fresh or cryopreserved patient tumor tissue into immunodeficient mice, preserving key histopathologic, genomic, and phenotypic characteristics more faithfully than many conventional cell-line-derived models. This makes PDX models highly relevant for oncology drug discovery, translational research, biomarker validation, co-clinical trial design, resistance-mechanism studies, and precision medicine workflows. The field is gaining scientific importance as oncology pipelines increasingly depend on clinically predictive models that can reflect interpatient heterogeneity, tumor evolution, stromal interactions, and therapy response patterns. Demand is being shaped by the rising global cancer burden, broader adoption of targeted therapies and immuno-oncology combinations, increased use of next-generation sequencing, and the need to de-risk late-stage clinical development through stronger translational evidence. At the same time, the PDX model landscape is constrained by engraftment variability, long model-development timelines, ethical expectations around animal use, and limitations in immune-system representation. As a result, the sector is moving toward more standardized, molecularly annotated, ethically governed, and computationally enabled model ecosystems that can support reproducible decision-making across academic, clinical, and biopharmaceutical research.

Transformative Shifts in the Patient-Derived Xenograft Model Landscape

The PDX model landscape is undergoing a shift from model generation as a standalone service toward integrated translational oncology platforms that combine tumor engraftment, genomic profiling, pharmacology, pathology, and bioinformatics. Researchers are prioritizing models with deep clinical annotation, including treatment history, molecular subtype, histology, and longitudinal response data, because these attributes improve relevance for patient stratification and biomarker-driven drug development. Humanized PDX models are becoming increasingly important for immuno-oncology studies, although technical complexity remains high because immune reconstitution, graft-versus-host risks, and donor variability can affect interpretation. Another major shift is the use of PDX-derived organoids, ex vivo drug screening, and matched in vivo studies to shorten decision cycles while preserving biological relevance. Standardization is also advancing through harmonized reporting of passage number, tumor take rate, authentication, quality control, genomic drift, and animal welfare practices. Regulatory and funding environments increasingly emphasize reproducibility, transparency, and reduction of unnecessary animal use, pushing laboratories toward carefully justified study designs and integrated alternatives where appropriate. Collectively, these shifts are transforming PDX models from exploratory tools into evidence-rich translational systems aligned with precision oncology and clinically informed therapeutic development.

Cumulative Impact of Artificial Intelligence on PDX Model Research

Artificial intelligence is increasingly reshaping PDX model development by improving the speed, reproducibility, and interpretability of translational oncology research. AI-enabled image analysis can support digital pathology workflows by quantifying tumor morphology, necrosis, mitotic activity, immune-cell patterns in humanized systems, and treatment-related histologic changes with greater consistency than manual review alone. Machine learning models are also being applied to integrate multi-omics datasets, drug-response results, clinical annotations, and tumor-growth kinetics to identify predictive biomarkers and prioritize therapeutic combinations. In study design, AI can help select the most relevant PDX cohorts based on molecular features, tumor type, and prior therapy exposure, supporting more efficient use of animals and better alignment with clinical hypotheses. Natural language processing can extract structured information from pathology reports and clinical records where permitted by privacy and governance frameworks, strengthening model annotation. However, AI adoption depends on high-quality data governance, standardized metadata, transparent model validation, bias mitigation, and secure handling of patient-derived information. The most meaningful impact will come from AI systems that are explainable, biologically grounded, and validated against independent datasets rather than from black-box automation. When combined with robust experimental design, artificial intelligence can improve the translational value of PDX models while supporting ethical and efficient oncology research.

Key Regional Insights Across Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is becoming a key region for PDX model research as cancer incidence, biomedical investment, and precision medicine programs expand across major economies. China, Japan, South Korea, India, Australia, and ASEAN research hubs are strengthening tumor biobanking, genomic medicine, and oncology trial infrastructure, supporting broader use of patient-derived tumor models in translational studies. North America remains deeply established in PDX model adoption due to mature oncology research networks, advanced sequencing capacity, strong academic medical centers, and widespread use of molecularly guided clinical trials. The United States and Canada benefit from well-developed ethical review systems and integrated cancer centers that support clinically annotated model generation. Latin America is advancing more selectively, with Brazil and Mexico playing important roles through cancer research institutions and growing interest in population-specific tumor biology, although infrastructure variability and funding constraints influence adoption. Europe demonstrates strong regulatory and scientific emphasis on reproducibility, animal welfare, and collaborative cancer research, with the European Union encouraging cross-border standards, biobanking governance, and data harmonization. The Middle East is investing in oncology care modernization, genomic medicine initiatives, and research capacity, particularly in GCC countries, where precision oncology programs are increasing demand for advanced preclinical platforms. Africa has emerging potential through cancer registry development, pathology capacity building, and collaborations focused on regionally relevant cancer types, but broader PDX model deployment remains linked to investments in biobanking, cold-chain logistics, ethical governance, and specialized animal facilities. Across all regions, adoption is most effective where clinical annotation, molecular profiling, biobank quality, and regulatory oversight converge.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO Research Ecosystems

ASEAN is gaining relevance in the PDX model ecosystem as member countries expand biomedical research, oncology diagnostics, and clinical trial participation, with opportunities tied to population-specific cancer patterns and regional biobank development. The GCC is strengthening its position through national health transformation programs, growing cancer care infrastructure, and investments in genomic medicine, creating a foundation for translational oncology platforms that can include PDX models when supported by specialized facilities and ethical frameworks. The European Union plays a central role in standard-setting, research collaboration, animal welfare governance, and data protection, making it influential in shaping how patient-derived tumor models are collected, annotated, shared, and validated. BRICS countries contribute substantial scientific capacity and diverse patient populations, with China, India, Brazil, Russia, and South Africa offering opportunities to study tumor heterogeneity across varied genetic, environmental, and healthcare contexts, although infrastructure maturity differs by country. The G7 remains highly influential because of advanced oncology research systems, extensive funding mechanisms, regulatory experience, and established academic-clinical networks that support sophisticated PDX applications in drug development and biomarker validation. NATO countries, while not a biomedical bloc by design, include many nations with strong life science research, secure data governance capabilities, and coordinated health-security priorities that can indirectly support resilient biomedical infrastructure. Across these groups, the most important differentiators are not geopolitical alignment alone, but the presence of high-quality biobanks, standardized consent processes, molecular diagnostics, animal welfare compliance, and interoperable data systems.

Key Country Insights Shaping Global PDX Model Adoption and Translational Use

The United States leads in PDX model utilization through dense oncology research networks, advanced molecular diagnostics, large-scale clinical trial activity, and translational cancer centers that integrate patient tissue acquisition with drug-response studies. Canada contributes through strong academic cancer programs, ethical governance, and population health research that supports clinically informed model development. Mexico and Brazil are important Latin American contributors, with opportunities linked to cancer-biology research, growing oncology infrastructure, and the need to represent regional tumor diversity in preclinical systems. The United Kingdom has a strong translational oncology base, supported by biobanking, genomics programs, and clinical research integration, while Germany, France, Italy, and Spain contribute through established biomedical research institutions, pathology expertise, and collaborative European cancer networks. Russia maintains oncology research capacity and scientific expertise, although international collaboration dynamics and infrastructure variability can influence cross-border model access. China has rapidly expanded precision medicine, tumor biobanking, sequencing capacity, and oncology drug development, making it highly active in patient-derived cancer model research. India's relevance is increasing due to its large and diverse patient population, expanding cancer centers, and growing genomic medicine capabilities, though standardization and infrastructure scale-up remain important. Japan is recognized for rigorous biomedical research, advanced oncology care, and strong interest in molecularly targeted therapies, supporting high-quality translational model use. Australia contributes through well-regarded cancer research groups, biobanking frameworks, and clinical-genomic studies, while South Korea is advancing rapidly through strong biotechnology infrastructure, digital health capabilities, and active oncology innovation. Across these countries, the strongest PDX model environments are those that connect patient consent, fresh tissue logistics, histopathology, molecular profiling, animal model expertise, and clinically relevant data interpretation into an integrated workflow.

Actionable Recommendations for Leaders in PDX Model Development

Industry leaders should prioritize clinically annotated, molecularly characterized PDX model repositories that align with specific oncology indications, molecular subtypes, and therapeutic mechanisms. Robust quality control should include tumor authentication, histopathologic comparison with the donor tumor, genomic stability monitoring, passage tracking, pathogen screening, and transparent documentation of engraftment conditions. Organizations should strengthen partnerships among hospitals, biobanks, pathology units, sequencing laboratories, animal facilities, and computational biology teams to reduce delays between tissue collection and model development. For immuno-oncology programs, leaders should carefully evaluate whether humanized PDX models, syngeneic models, organoids, or integrated multi-model strategies best fit the scientific question. Ethical leadership is essential: study designs should follow the principles of replacement, reduction, and refinement, with clear justification for animal use and incorporation of ex vivo or in silico tools where scientifically valid. Data strategy should receive equal attention, including harmonized metadata, privacy-preserving clinical annotation, interoperable databases, and AI-ready datasets. Decision-makers should also invest in reproducibility by using standardized protocols, independent validation cohorts, and predefined response criteria. Finally, PDX model programs should be positioned as part of a broader translational evidence framework rather than as isolated experiments, ensuring that findings connect to biomarker strategy, patient stratification, clinical trial design, and therapeutic portfolio decisions.

Research Methodology Grounded in Verified Translational Oncology Evidence

This executive summary is developed using a secondary research methodology focused on verified scientific, regulatory, and industry-relevant sources. The approach includes review of peer-reviewed oncology and translational medicine literature, public health and cancer research publications, regulatory guidance on preclinical research and animal welfare, publicly available information from cancer research networks, and documented best practices in biobanking, pathology, genomics, and patient-derived model development. The analysis emphasizes qualitative evidence on adoption drivers, technology trends, regional capabilities, ethical considerations, and operational barriers while deliberately excluding market sizing, market share, and forecasting. Cross-validation is performed by comparing findings across multiple credible source categories, including academic publications, clinical research frameworks, public cancer statistics, and recognized standards for laboratory practice and animal research governance. Particular attention is given to reproducibility, data integrity, informed consent, patient privacy, model characterization, and translational relevance. Insights are synthesized into narrative sections to support strategic decision-making for stakeholders involved in oncology drug discovery, biomarker development, precision medicine, and translational cancer research.

Conclusion: PDX Models as a Strategic Bridge to Precision Oncology

Patient-derived xenograft models remain a vital component of precision oncology research because they can preserve clinically relevant tumor biology and support evaluation of therapeutic response in biologically complex systems. Their value is highest when they are supported by strong clinical annotation, molecular profiling, rigorous quality control, and ethically responsible animal research practices. The field is moving toward integrated platforms that combine PDX models with organoids, digital pathology, multi-omics, humanized systems, and artificial intelligence to improve translational confidence and reduce inefficiencies in oncology development. Regional and country-level adoption will continue to depend on cancer research infrastructure, biobanking maturity, genomic medicine capacity, specialized animal facilities, and governance frameworks for patient-derived data and tissue. For industry leaders, success will depend on building reproducible, AI-ready, and clinically aligned PDX model ecosystems that can translate biological complexity into actionable oncology insights. By treating PDX models as part of a broader evidence-generation strategy, researchers can better support biomarker discovery, therapeutic prioritization, and precision medicine advancement without overreliance on any single preclinical platform.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Patient-Derived Xenograft/PDX Model Market, by Type

• 7.1. Introduction
• 7.2. Mice Models
• 7.3. Rat Models

8. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

• 8.1. Introduction
• 8.2. Gastrointestinal
• 8.3. Gynecological
• 8.4. Hematological
• 8.5. Respiratory
• 8.6. Urological

9. Patient-Derived Xenograft/PDX Model Market, by Study Type

• 9.1. Introduction
• 9.2. Ex-vivo
• 9.3. In-vitro
• 9.4. In-vivo

10. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

• 10.1. Introduction
• 10.2. Heterotopic
• 10.3. Orthotopic
• 10.4. Subcutaneous

11. Patient-Derived Xenograft/PDX Model Market, by Application

• 11.1. Introduction
• 11.2. Basic Cancer Research
• 11.3. Biomarker Discovery
• 11.4. Genomic & Molecular Studies
• 11.5. Personalized Medicine
• 11.6. Preclinical Drug Evaluation
• 11.7. Tumor Microenvironment Analysis

12. Patient-Derived Xenograft/PDX Model Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Patient-Derived Xenograft/PDX Model Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Patient-Derived Xenograft/PDX Model Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abnova Corporation
• 16.2. Altogen Labs
• 16.3. Biocytogen
• 16.4. BioDuro LLC
• 16.5. BioReperia AB
• 16.6. Certis Oncology Solutions
• 16.7. Champions Oncology, Inc.
• 16.8. Charles River Laboratories International, Inc.
• 16.9. Creative Animodel
• 16.10. Creative Biolabs
• 16.11. Crown Bioscience by JSR Corporation
• 16.12. EPO Berlin-Buch GmbH
• 16.13. GemPharmatech Co. Ltd.
• 16.14. Genesis Drug Discovery & Development
• 16.15. Hera Biolabs
• 16.16. HOIST Co.,Ltd.
• 16.17. InnoSer
• 16.18. Inotiv, Inc.
• 16.19. Laboratory Corporation of America Holdings
• 16.20. LIDE Shanghai Biotech, Ltd
• 16.21. Mediford Corporation by PHC Holdings Corporation
• 16.22. Oncodesign Services
• 16.23. Shanghai ChemPartner
• 16.24. Shanghai Medicilon Inc.
• 16.25. TheraIndx Lifesciences Pvt. Ltd.
• 16.26. Urosphere SAS
• 16.27. WuXi AppTec Co., Ltd.
• 16.28. Xentech